Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PTGX
- Price
- 42.62
- Stock movement up
- +1.73 (4.23%)
- Company name
- Protagonist Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.54B
- Ent value
- 2.48B
- Price/Sales
- 7.84
- Price/Book
- 4.78
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 14.87
- Forward P/E
- -
- PEG
- -
- EPS growth
- -4.38%
- 1 year return
- 52.87%
- 3 year return
- 20.27%
- 5 year return
- 45.79%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PTGX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 14.87 |
| Price to OCF | 11.03 |
| Price to FCF | 11.08 |
| Price to EBITDA | 16.78 |
| EV to EBITDA | 16.39 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.84 |
| Price to Book | 4.78 |
| EV to Sales | 7.66 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 59.60M |
| EPS (TTM) | 2.77 |
| FCF per share (TTM) | 3.71 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 323.80M |
| Gross profit (TTM) | 321.25M |
| Operating income (TTM) | 149.11M |
| Net income (TTM) | 170.85M |
| EPS (TTM) | 2.77 |
| EPS (1y forward) | -1.35 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.21% |
| Operating margin (TTM) | 46.05% |
| Profit margin (TTM) | 52.76% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 131.12M |
| Net receivables | 2.67M |
| Total current assets | 476.77M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 19.23M |
| Total assets | 603.86M |
| Accounts payable | 3.05M |
| Short/Current long term debt | 10.90M |
| Total current liabilities | 44.58M |
| Total liabilities | 71.94M |
| Shareholder's equity | 531.91M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 230.29M |
| Capital expenditures (TTM) | 1.06M |
| Free cash flow (TTM) | 229.23M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 32.12% |
| Return on Assets | 28.29% |
| Return on Invested Capital | 32.12% |
| Cash Return on Invested Capital | 43.09% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 41.10 |
| Daily high | 42.63 |
| Daily low | 41.10 |
| Daily Volume | 1.16M |
| All-time high | 59.76 |
| 1y analyst estimate | 57.50 |
| Beta | 2.16 |
| EPS (TTM) | 2.77 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| PTGX | S&P500 | |
| Current price drop from All-time high | -28.68% | -12.89% |
| Highest price drop | -85.79% | -56.47% |
| Date of highest drop | 13 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -44.97% | -11.07% |
| Avg time to new high | 36 days | 12 days |
| Max time to new high | 1055 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.54B
Marketcap category
Mid-cap
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Employees
126
Investor relations
-
SEC filings
CEO
Dinesh V. Patel
Country
USA
City
Newark
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page